STING
Stimulator of Interferon Genes; TMEM173; MITA; ERIS; MPYS
Stimulator of interferon genes (STING) is an integral ER-membrane protein that can be activated by 2'3'-cGAMP synthesized by cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS) upon binding of double-stranded DNA. It activates interferon (IFN) and inflammatory cytokine responses to defend against infection by microorganisms.
STING is a key cytosolic receptor for small nucleotides and plays a key role in anticancer and antiviral immunity. STING signaling pathway is also a critical link between innate and adaptive immunity, and induces anti-tumor immune responses. STING agonists, such as endogenous cyclic dinucleotide (CDN) cyclic GMP-AMP (cGAMP), have been used in diverse research for immunogenic tumor clearance, antiviral treatments and vaccine adjuvants.
All Product Categories
-
STING Inhibitors
(52)
View all products
-
STING Agonists
(105)
View all products
-
STING Antagonists
(8)
View all products
-
STING Activators
(53)
View all products
-
STING Modulators
(5)
View all products
-
STING Degraders
(12)
View all products
-
STING Controls
(3)
View all products
-
STING Ligands
(3)
View all products
-
STING Related Products (259)
Related Products (259)
-
Antibodies (13)
-
STING-IN-16
0 ImagesCat. No.: HY-175210CAS No.: 2982807-58-7STING-IN-16 is a STING inhibitor with IC50 values of 44 nM (human) and 32 nM (mice) for cellular STING inhibition. STING-IN-16 effectively inhibits the activation of the STING axis in both human and murine cells. STING-IN-16 can restore renal mitochondrial function, suppress reactive oxygen species (ROS) production, and reduce cell apoptosis. STING-IN-16 shows robust anti-inflammatory efiicacy in vivo. STING-IN-16 can be used for the study of autoimmune and autoinflammatory diseases.
-
c-(2'FdAMP-2'FdIMP)
0 ImagesCat. No.: HY-112880CAS No.: 1951464-78-0c-(2'FdAMP-2'FdIMP) (Compound 52),a derivative of cAIMP (HY-134375), is a cyclic dinucleotide (CDN). c-(2'FdAMP-2'FdIMP) is a STING activator and significantly induce STING-dependent IRF and NF-κB pathway signaling. c-(2'FdAMP-2'FdIMP) can be used for STING-based immunotherapy, such as cancers and infectious diseases research.
-
SN38-(PEG)2-Pom-α
0 ImagesCat. No.: HY-180555SN38-(PEG)2-Pom-α is a selective PROTAC RPL15 degrader. SN38-(PEG)2-Pom-α induces ubiquitin-mediated degradation of RPL15 without affecting TOP1. SN38-(PEG)2-Pom-α induces damage-associated molecular pattern (DAMP) secretion from cancer cells, which activated cGAS-STING signaling in dendritic cells. SN38-(PEG)2-Pom-α enhances anti-PD-1 immunotherapy in a murine melanoma tumor model expressing human CRBN. SN38-(PEG)2-Pom-α can be used for melanoma research.
-
ZSA-215
0 ImagesCat. No.: HY-174308ZSA-215 is a potent and orally active STING agonist with an EC50 of 3.3 μM. ZSA-215 enhances STING signaling through promoting the phosphorylation of STING and interferon regulatory factor 3 (IRF3) and secretion of IFN-β. ZSA-215 inhibits tumor regression and long-term survival of mice in MC38 colon cancer model. ZSA-215 can be used to the study of colon cancerr.
-
UM-232
0 ImagesCat. No.: HY-184593UM-232 is a highly selective covalent STING antagonist with an EC50 of 6.20 μM in STING R232-expressing THP-1 cells. UM-232 covalently targets C292 and C309 cysteines of STING, blocks STING oligomerization and inhibits downstream TBK1/IRF3 activation and proinflammatory cytokine transcription. UM-232 has low off-target reactivity and good hepatic stability, serving as a chemical probe for STING-driven autoimmune and inflammatory diseases including Aicardi-Goutières syndrome (AGS), Systemic Lupus Erythematosus (SLE) and Amyotrophic Lateral Sclerosis (ALS).
-
STING agonist-25
0 ImagesCat. No.: HY-152958CAS No.: 2408723-10-2STING agonist-25 (CF505) is a non-nucleotide small-molecule STING agonist. STING agonist-23 activates STING, increases phosphorylation of STING, TBK1 and IRF3. STING agonist-23 promotes the levels of IFN-β, IL-6, CXCL-10, TNF-α, ISG-15, and CCL-5 in tumor cells. STING agonist-23 exhibits activity against SARS-CoV series strains.
-
UM-200
0 ImagesCat. No.: HY-182923UM-200 is a covalent STING inhibitor with an EC50 of 1.10 μM. UM-200 covalently modifies the cysteine residues C292 or C309 of STING, thereby blocking its oligomerization and downstream signal transduction. UM-200 inhibits STING-dependent phosphorylation of TBK1 and IRF3. UM-200 inhibits the STING signaling pathway in mouse models. UM-200 can be used for research on STING-driven inflammatory and autoimmune diseases.
-
TLC388
0 ImagesCat. No.: HY-19943CAS No.: 1432468-79-5TLC388 is a novel camptothecin analog with limited antitumor activity in metastatic NEC.
-
STING Degrader-3
0 ImagesCat. No.: HY-168554STING Degrader-3 is a PROTAC-like STING degrader with a DC50 of 2.58 μM in THP-1 cells. STING Degrader-3 degrades STING protein via the lysosomal pathway. STING Degrader-3 functions as a non-degradative inhibitor in macrophages. STING Degrader-3 reduces the phosphorylation levels of TBK1 and IRF3, and downregulates the expression of IFN-β, CXCL10, IL-6, TNFα, IL-1β, ISG15 and ISG56. STING Degrader-3 exhibits renoprotective properties in a cisplatin-induced acute kidney injury model. STING Degrader-3 can be used in studies related to acute kidney injury. ((Pink: STING ligand (HY-168676); Blue: CRBN ligand (HY-126457); Black: linker (HY-W123015); CRBN ligand + linker: (HY-168677)).
-
MS8588
0 ImagesCat. No.: HY-162967CAS No.: 3060519-94-7MS8588 is a deubiquitinase-targeting chimera (DUBTAC) against cGAS. MS8588 induces targeted stabilization of cGAS, thereby activating downstream signaling pathways. MS8588 activates the cGAS/STING/IRF3 innate immune signaling pathway. MS8588 exhibits antitumor activity.
-
Polθ-IN-11
0 ImagesCat. No.: HY-183748CAS No.: 3082173-75-6Polθ-IN-11 is an orally active DNA polymerase θ (Polθ) ATPase inhibitor with an IC50 of 4.3 nM against human targets. Polθ-IN-11 activates the cGAS-STING pathway. Polθ-IN-11 upregulates the expression of PD-L1 in HR-deficient cancer cells. Polθ-IN-11 acts synergistically with PARP inhibition in HR-deficient cancer cells and in vivo xenograft models. Polθ-IN-11 can be used in studies related to HR-deficient cancers.
-
Mal-Val-Ala-PAB-4-Abu(Me)-Dazostinag
0 ImagesCat. No.: HY-158349CAS No.: 2553413-19-5Mal-Val-Ala-PAB-4-Abu(Me)-Dazostinag is a drug-linker conjugate for ADC.
-
PDIC-NN
0 ImagesCat. No.: HY-169225CAS No.: 932740-48-2Synonyms: PDIC-NS free basePDIC-NN (PDIC-NS free base) is a STING activator with anticancer activity. PDIC-NN promotes the content and biostability of endogenous cyclic dinucleotides (CDNs). PDIC-NN triggers ROS burst and causes serious damage to mitochondria. PDIC-NN induces cell apoptosis and inhibits DNA replication. PDIC-NN activates cGAS-STING signaling pathway, enhances the immunogenicity of tumor cells and activates a robust innate immune response.
-
STING agonist-30
0 ImagesCat. No.: HY-149267CAS No.: 2951078-67-2
-
MS7829
0 ImagesCat. No.: HY-162966CAS No.: 3060519-67-4MS7829 is a deubiquitinase-targeting chimera (DUBTAC) that targets cGAS. MS7829 recruits OTUB1 to cGAS, binds covalently to OTUB1, stabilizes the protein abundance of cGAS, and activates the cGAS-STING-IRF3 innate immune signaling pathway in an OTUB1-dependent manner. MS7829 is applicable to cancer-related research.
-
Ferroptosis inducer-17
0 ImagesCat. No.: HY-184662Ferroptosis inducer-17 is a ferroptosis inducer that downregulates GPX4 and activates the CTSB and cGAS-STING pathways. Ferroptosis inducer-17 exhibits cytotoxicity against cancer cells but low toxicity toward normal cells. Ferroptosis inducer-17 accumulates in mitochondria and lysosomes, thereby inducing ROS production, lipid peroxidation, mitochondrial membrane depolarization, lysosomal iron accumulation, increased membrane permeability, and enhanced oxidative stress. Ferroptosis inducer-17 inhibits tumor growth in cisplatin-resistant xenograft models. Ferroptosis inducer-17 can be used for cancer-related research.
-
CDN-A
0 ImagesCat. No.: HY-148420CAS No.: 2586047-09-6CDN-A is a cyclic di-nucleotide, it can be used to synthesis antibody-drug conjugate (ADC). Cyclic di-nucleotides are potent stimulators of innate and adaptive immune responses. In humans, cyclic di-nucleotide, which are either produced endogenously in response to foreign DNA or by invading bacterial pathogens, trigger the innate immune system by activating the expression of interferon genes.
